Govt in talks with SII for Nipah antibody, may put imports on hold

Given the recurring outbreaks in the last five years, the government is considering domestic manufacturing of monoclonal antibodies for treating Nipah virus infections and is in talks with Serum......

Antidote against Nipah reaches Kerala; expert panel to decide further action

In the wake of the Nipah outbreak in Kozhikode district of Kerala, Indian Council of Medical Research has delivered the antibody requested by the state to combat the deadly virus. A mobile......

Nipah situation not as scary as in 2018, says K K Shailaja

Former Health Minister and senior ruling Communist Party of India-Marxist MLA K K Shailaja says Kerala has nothing to worry about the Nipah outbreak in Kozhikode as the situation is not as scary as......

Health worker tests positive as Kerala reports fifth Nipah case

A 24 year-old health worker has become Kerala's fifth confirmed Nipah case since its recent outbreak, as the government stepped up its efforts to cure a 9 year-old boy suffering from the deadly......

Sales of Biocon's itolizumab surge as phase-4 clinical trials begin

In India, itolizumab, known by the brand name Alzumab, has been priced at Rs 8,000 per vial. Most patients require four vials for Covid-19 treatment, taking the cost of the therapy to Rs 32,000.......

Glenmark's favipiravir under fire for 'misguided' claims of Covid-19 drug

The Drug Controller General of India has sent a letter to the Glenmark seeking clarifications on pricing as well as claims of therapeutic efficacy. While Glenmark has claimed this drug is effective......

With Covid-19 claims of Rs 300cr, insurance cos get a rate card

Insurance experts said since it may be difficult to set a tariff or fixed rates for Covid-19 treatment, an indicative rate chart has been proposed. IMAGE: Medical workers wearing personal......

Glenmark to conduct trials of potential COVID-19 drug

As per the clinical trial protocol approved, 150 subjects with mild to moderate COVID-19 will be randomised in the study in a 1:1 ratio to Favipiravir with standard supportive care or standalone......